AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03465631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART Glove system with tDCS
Description: combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
Study NCT03465631 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SMART Glove system with sham-tDCS
Description: combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
Study NCT00112931 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00112931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment
Study NCT03725514 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Conventional Blood Clot Technique
Study NCT03725514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF
Description: Platelet Rich Fibrin Technique
Study NCT04485273 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
Study NCT04485273 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
Study NCT04485273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane in air/oxygen mixture of 40% is titrated to achieve adequate depth of anesthesia.
Study NCT04485273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane in air/oxygen mixture of 40% is titrated to achieve adequate depth of anesthesia.
Study NCT04485273 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Subtenon's Block
Description: Subtenon's block is performed in the eye undergoing surgery under sterile conditions where a 19-gauge curved blunt metallic cannula (25 mm) is inserted into sub-tenon's space.
Study NCT04485273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subtenon's Block
Description: Subtenon's block is performed in the eye undergoing surgery under sterile conditions where a 19-gauge curved blunt metallic cannula (25 mm) is inserted into sub-tenon's space.
Study NCT04485273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic Solution and Dexmedetomedine
Description: The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg), in addition to dexmedetomedine (0.5 μg /kg)
Study NCT04485273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local Anesthetic Solution
Description: The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg).
Study NCT01283230 — intervention group
Intervention type: DEVICE
Intervention: Acoustic radiation force impulse imaging
Description: Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
Study NCT02760953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Using a novel cryoablation unit to perform transurethral cryoablation on the tumor base after transurethral resection
Study NCT02760953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin instillation should be give within 24 hours after initial TUR, this is accord with current guideline.
Study NCT03004937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Medicine Hearing Loss Best Practice Alert
Description: A Best Practice Alert, or BPA, was created in the electronic medical record system, which fires when patients meet the inclusion criteria. It reminds providers to ask their patients if they think have a hearing loss and allows them to respond as needed (refer to audiology, add hearing loss to the problem summary list, or dismiss for one year).
Study NCT03189004 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh
Description: 1. Identification and registration of pregnant women and services for them~2. Birth notification~3. Childhood vaccination services under EPI~4. Newly married couple identification~5. e-Referral.~6. e-monitoring
Study NCT03771586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: SAGE-718 in combination with Ketamine
Study NCT03771586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in combination with Ketamine
Study NCT03157505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purethal Birch immunotherapy
Description: Purethal birch was administered as perennial therapy: 24 months
Study NCT03157505 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and symptomatic treatment
Description: symptomatic treatment including: antihitamine drug, nasal dropps and placebo injection
Study NCT03840694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Smoking Abstinence
Description: Participants will abstain from smoking for 24 hours.
Study NCT03840694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ad Lib Smoking
Description: Participants will continue smoking as usual (i.e. ad lib) and smoke one cigarette of their own brand immediately prior to scanning.
Study NCT03203421 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1 LS2
Description: A viral vectored vaccine, using a chimpanzee adenovirus as a vector encoding malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain.
Study NCT03203421 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA LS2
Description: Modified vaccinia Ankara vector encoding liver-stage dual antigen LS2 (LSA1 ad LSAP2) fused to the C-terminal end of the leader sequence of tPA.
Study NCT02838082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Protocol
Description: Sleep Hygiene Protocol involving 1) Improved sleep environment 2) Enhanced Circadian Stimuli 3) Increased Daytime Activation (blue light therapy, daytime light exposure and daytime sleep restriction) 4) Adjusted morning ADL routines and 5) Restricted Caffeine intake
Study NCT02838082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: All standard of care procedures in a specialized traumatic brain injury inpatient rehabilitation unit
Study NCT00813319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls OnGuard
Description: Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
Study NCT02012296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enzalutamide
Description: Given PO
Study NCT02012296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Given PO
Study NCT02012296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: Given PO
Study NCT02012296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02012296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02012296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT02012296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04616196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: NKTR-255 IV every 21 days
Study NCT04616196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given at specified doses on specified days
Study NCT03618186 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tau PET scan
Description: Patient will receive a dose of flutaucipir and be scanned appropriately
Study NCT01889303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC
Description: Docetaxel plus cisplatin chemotherapy regimen was delivered as chemotherapy and concurrent chemoradiotherapy.~chemotherapy regimen: Docetaxel（Qilu Pharma. China） 75mg iv D1, Cisplatin（Qilu Pharma. China） 75mg iv D1 ,Q3W for 2 cycles, then Docetaxel 35mg iv D1, Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy( 5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W for 2 cycles.
Study NCT01889303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy with 5-FU/CF
Description: FOLFOX6 regiment was delivered as adjuvant chemotherapy and 5-FU/CF as concurrent chemotherapy treatment.~Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui Medicine Co., Ltd，China） 400mg/m2 IV bolus d1, followed with 2400mg/m2 over 46h continuous infusion Q2Wx3 cycles of chemotherapy Concurrent chemotherapy : 5-FU 400mg/m2 IV and Leucovorin 20mg/m2 IV were given on the first four and the last three days in the period of radiotherapy. After radiation, patients will have a rest lasting for 4 weeks and then given Folxof6 regiment chemotherapy for 3 cycles.
Study NCT01889303 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: Therapy plan system was formulated by CT simulation. Radiation was delivered with 15MV photons in both Arm A and Arm B. Radiotherapy consisted of 45Gy of radiation at 1.8Gy/day, five days per week for 5 weeks, to the tumor bed, to the margins of resection, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
Study NCT01889303 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: Therapy plan system was formulated by CT simulation. Radiation was delivered with 15MV photons in both Arm A and Arm B. Radiotherapy consisted of 45Gy of radiation at 1.8Gy/day, five days per week for 5 weeks, to the tumor bed, to the margins of resection, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
Study NCT01326078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 3 - 4 mg/kg IV, adjustment dose if necessary
Study NCT01326078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: 3 - 4 mg/kg IV, adjustment dose if necessary
Study NCT00838214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: 3mg capsule, 3x per day for 6 months
Study NCT00838214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
Study NCT02433171 — intervention group
Intervention type: PROCEDURE
Intervention: Standard of Care FDG-PET Imaging
Description: \[11C\]Methionine \[11\]. This natural amino acid, and its various fluorinated derivatives, has been widely used in brain tumor studies due to a) high tumor-to-normal brain contrast, and b) its sensitivity to biological functions including amino acid transport and utilization. \[11C\]PBR28 \[12\]. This ligand is one of a series of second-generation tracers that bind to TSPO (translocator protein), a protein that is upregulated in activated microglia.
Study NCT04830150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive interventions on the stress levels of mothers of infants hospitalized in the Neonatal Intensive Care Unit (NICU).
Description: This study was conducted to determine the effects of supportive interventions on the stress levels of mothers of infants hospitalized in the Neonatal Intensive Care Unit (NICU).
Study NCT01968395 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Caspofungin 70 mg
Description: Intravenous use
Study NCT01580033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A+C+hib Conjugate Vaccine
Description: The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose
Study NCT01580033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose
Study NCT01580033 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A+C Vaccine
Description: The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
Study NCT01580033 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib vaccine
Description: The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
Study NCT04433806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to weight loss program
Description: 16 weeks Diabetes Prevention Program based weight loss program at a local community partner
Study NCT02982239 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep Diary
Description: All 40 chosen students will be provided a link to complete a daily sleep diary for 10 weeks. Sleep diary will assess activity before bed, bedtime, time to fall asleep, number of awakenings, time awake after sleep onset, time out of bed, time of final awakening, perceived sleep quality. Diary also asks about naps taken during the day, caffeine and tobacco consumption, and an additional space for open-ended comments from the participant.
Study NCT02982239 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fitness tracker
Description: All 40 chosen students will receive a fitness tracker. The fit bit will estimate sleep and physical activity as well as adherence to the program. participants will have access to their own data. Data will also be monitored from the lab using Fitabase which provides access to day, hour, and minute-level resolution of data for steps taken, intensity class, calories burned, and sleep (length, movement, and quality).
Study NCT02982239 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Blue-Blocking Glasses
Description: Half of the 40 chosen students (N=20) will be provided with blue blocking glasses. The blue-blocking glasses will ensure that blue light from electronic devices will not interfere with circadian rhythm or sleep onset, and allow students to fall asleep earlier.
Study NCT02982239 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LED light
Description: Half of the 40 chosen students (N=20) will be provided with a bright LED light. The bright LED light will provide bright blue light in the morning to help students wake and an amber light to promote earlier bedtimes.
Study NCT02982239 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information Session
Description: all 40 participants will attend a 1-hour information session about sleep delivered by the PIs, to be followed by a 1-hour Q\&A period.~Peer educators will receive and extra 1-hour training session on how to handle questions and when to refer back to the PIs.
Study NCT02982239 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text messages
Description: All participants will receive text messages in the evening that will include adherence reminders, encouraging statements, and tips for improving sleep. Messages will be randomized, with no more than 3 messages of any type per week. Messages will serve as a cue to action without being overly repetitive or predictable.
Study NCT01145716 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopy, surgery
Description: Ulno-volar wrist approach to the TFCC
Study NCT03767036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride 25 mg capsule
Description: Capsule with tramadol hydrochloride 25 mg; Product of Grünenthal de Mexico S.A. de C.V.
Study NCT03767036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 25 mg capsule
Description: Capsule with tramadol hydrochloride 25 mg; Product of Grünenthal de Mexico S.A. de C.V.
Study NCT03767036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine 10 mg tablet
Description: Tablet with ketorolac tromethamine 10 mg; Product of Siegfried Rhein, S.A. de C.V., Mexico
Study NCT03767036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine 10 mg tablet
Description: Tablet with ketorolac tromethamine 10 mg; Product of Siegfried Rhein, S.A. de C.V., Mexico
Study NCT04090853 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Venus Bliss
Description: The investigational device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1064 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
Study NCT04299191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM561
Description: Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general criterion) is met.~The starting dose will be 2.8 g/m2 twice daily. If tolerated, doses will be escalated to 3.5 g/m2 twice daily and then to a third dose level of 4.2 g/m2 twice daily. These dose levels correspond to 80%, 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. A total of 3 dose cohorts are anticipated for the dose escalation phase of the study, with up to 6 patients enrolled at each dose level according to a standard 3+3 design. During each dose cohort, at least 1 week must elapse between the first and subsequent patients receiving treatment with LAM561.
Study NCT00846651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colloid administration
Description: The patients received 0.5 L colloid solution (hydroxyethylstarch 6%) or 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
Study NCT00846651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid administration
Description: The patients received 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
Study NCT00846651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine infusion
Description: A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
Study NCT00846651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine infusion
Description: A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
Study NCT01794520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Each dose of venetoclax was to be taken with approximately 240 mL of water. On days that pre-dose pharmacokinetic (PK) sampling was required, dosing was to occur in the morning at the clinic at approximately 0900 (± 1 hour) to facilitate PK sampling. Dose Escalation cohort participants were to take venetoclax within 30 minutes after the completion of a standard low-fat breakfast with approximately 240 mL of water on Cycle 2 Day 1. On all other dosing days, participants were instructed to take venetoclax orally QD within 30 minutes after the completion of a low-fat breakfast. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed.
Study NCT01794520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets were administered by mouth per the dexamethasone prescribing information.
Study NCT02276664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help (SHI)
Description: The newly revised Stop Smoking for Good booklets.
Study NCT02276664 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: The existing Clearing the Air smoking-cessation manual published by the National Cancer Institute (NCI).
Study NCT04327830 — intervention group
Intervention type: OTHER
Intervention: Decisional needs assessment
Description: Assessment of decision-making needs